Personalized Care for Patients with Advanced Non-small Cell Lung Carcinoma: Selecting Targeted Agents and Sequence of Therapy to Improve Patients (Nursing)

Target Audience:

This activity is designed to meet the educational needs of oncologists, oncology nurses, pathologists, radiologists, pharmacists, and other healthcare practitioners who care for patients with lung cancer.

Program Overview:

This case-based activity will cover the diagnosis and management of patients with Non-small Cell Lung Carcinoma.

Disclosure Of Unlabeled Use:

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, Drs. Ramalingam and Socinski may mention the use of medications for both FDA-approved and non-approved indications.

Disclaimer:

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

Method Of Participation:

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete the post-test and activity evaluation
  4. Physicians who successfully complete the post-test and evaluation will receive CME credit.
  5. All non-physician participants who successfully complete the post-test and evaluation will receive a certificate of participation.
  6. All nurses will receive a CNE certificate.
You will receive your certificate via email.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com

Course Viewing Requirements:

PC
Internet Explorer (v6 or greater), or Firefox

MAC
Safari

RELEASE DATE: April 30, 2014
EXPIRATION DATE: April 30, 2015

MEDIUM: Internet

Estimated Time to Complete This Educational Activity: 60 minutes

Participation Statement:

This educational activity provides training necessary for licensed attendees to maintain state licensing requirements. The tuition for this educational activity is subsidized in part by unrestricted educational grants, including for those attendees who have successfully completed the state licensing requirements for their respective fields. This subsidy is reflected in the registration fees for this activity.

Accreditation:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation:

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

Faculty Listing:

Suresh Ramalingam, MD
Associate Professor
Director of Medical Oncology
Emory University Winship Cancer Institute
Atlanta, GA


Mark A. Socinksi, MD
Professor of Medicine and Cardiothoracic Surgery
Director, Lung Cancer Section, Division of Hematology/Oncology
Clinical Associate Director, Lung SPORE
University of Pittsburgh
Philadelphia, Pennsylvania

Course Reviewer:

Katherine Galluzzi, DO, CMD, FACOFP dist.
Professor and Chairperson, Department of Geriatrics
Philadelphia College of Osteopathic Medicine
Attending Physician, Family Medicine
Tenet Roborough Memorial Hospital
Philadelphia, Pennsylvania

 

CCM/UMA Lead Nurse Planner:

Margaret Governo, EdD, APRN BC
CCM Lead Nurse Planner
Ultimate Medical Academy

Objectives:

  • Review histological and molecular tests that can be used to personalize care for advanced NSCLC in multiple lines of therapy in different settings (academic vs. community practice)
  • Critically evaluate clinical data of emerging targeted approaches and combination strategies for the treatment of advanced NSCLC (and for overcoming resistance to previous treatments)
  • Apply evidence from clinical trials to the choice of switch and maintenance regimens for advanced NSCLC in the clinic

Financial Disclosure:

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Course Chair - - Dr. Ramalingam serves as a consultant for Amgen, Aveo, Ariad, Boehringer Ingelheim, Genentech, Gilead, Lilly and Novartis.
Course Chair - - Dr. Socinski has no financial relationships to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, Vice President of Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Flavia Piazza, VP, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Sarah Taegder, Director of Accounts for Med Learning Group has nothing to disclose.